CL2017000373A1 - Diagnóstico de cáncer y terapia. - Google Patents

Diagnóstico de cáncer y terapia.

Info

Publication number
CL2017000373A1
CL2017000373A1 CL2017000373A CL2017000373A CL2017000373A1 CL 2017000373 A1 CL2017000373 A1 CL 2017000373A1 CL 2017000373 A CL2017000373 A CL 2017000373A CL 2017000373 A CL2017000373 A CL 2017000373A CL 2017000373 A1 CL2017000373 A1 CL 2017000373A1
Authority
CL
Chile
Prior art keywords
therapy
cancer diagnosis
receptor
angiotensin
present
Prior art date
Application number
CL2017000373A
Other languages
English (en)
Inventor
Ranui Francesca Baillie
Paul Frank Davis
Tinte Itinteang
Swee Thong Tan
Original Assignee
Gillies Mcindoe Res Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gillies Mcindoe Res Institute filed Critical Gillies Mcindoe Res Institute
Publication of CL2017000373A1 publication Critical patent/CL2017000373A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN PROPORCIONA UN NUEVO ENFOQUE PARA EL DIAGNÓSTICO Y LA TERAPIA DE CÁNCER, PROPORCIONANDO COMPOSICIONES Y MÉTODOS PARA LA IDENTIFICACIÓN Y LA IDENTIFICACIÓN ESPECÍFICA DE LAS POBLACIONES DE CÉLULAS MADRE DE CÁNCER PRESENTES EN UN TUMOR A ERRADICAR O RETRASAR O PREVENIR (5) CRECER Y PROPAGAR, INCLUYENDO EL POTENCIAL DE METÁSTASIS TUMORAL, POR LA MODULACIÓN DEL SISTEMA RENINA-ANGIOTENSINA, INCLUYENDO, PERO NO LIMITADO A, LA RENINA RECEPTOR, RECEPTOR DE ANGIOTENSINA II(2) Y UNA FORMA SECRETADA DEL RECEPTOR DE RENINA.</p>
CL2017000373A 2014-08-12 2017-02-13 Diagnóstico de cáncer y terapia. CL2017000373A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462036583P 2014-08-12 2014-08-12

Publications (1)

Publication Number Publication Date
CL2017000373A1 true CL2017000373A1 (es) 2018-01-12

Family

ID=55304402

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000373A CL2017000373A1 (es) 2014-08-12 2017-02-13 Diagnóstico de cáncer y terapia.

Country Status (12)

Country Link
US (2) US10281472B2 (es)
EP (1) EP3180000A4 (es)
JP (1) JP6899771B2 (es)
KR (1) KR20170040804A (es)
CN (1) CN106999471A (es)
AU (1) AU2015302419B2 (es)
BR (1) BR112017002724A2 (es)
CA (1) CA2957930A1 (es)
CL (1) CL2017000373A1 (es)
MX (1) MX2017001954A (es)
SG (2) SG10201901157QA (es)
WO (1) WO2016024870A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017095236A1 (en) * 2015-11-30 2017-06-08 Gillies Mcindoe Research Institute Treatment of fibrotic conditions
US20170360829A1 (en) * 2016-01-27 2017-12-21 Gillies Mcindoe Research Institute Treatment of vascular anomalies
WO2017207656A1 (en) * 2016-05-31 2017-12-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Atp6ap2 inhibition for treating or preventing a tumoural and/or proliferative disorder of the central nervous system
EP3576746A4 (en) * 2017-01-31 2020-09-09 Gillies Mcindoe Research Institute THERAPEUTICS AGAINST CANCER
WO2019079222A1 (en) 2017-10-16 2019-04-25 Board Of Regents Of The University Of Texas System COMPOSITIONS FOR INHIBITING 3 'REPLACEMENT EXONUCLEASE 2 AND SCREENING METHODS FOR SUCH COMPOSITIONS
WO2019084057A2 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
US20190133974A1 (en) 2017-11-07 2019-05-09 University Of South Florida Methods for detecting and treating propranolol sensitive tumors
CA3103714A1 (en) * 2018-06-13 2019-12-19 23Ikigai Pte Ltd Method for analysing pluripotent stem cell biomarkers, and implementations thereof
WO2020027665A1 (en) * 2018-07-30 2020-02-06 Gillies Mcindoe Research Institute Novel pharmaceutical compositions for cancer therapy
WO2020028007A1 (en) * 2018-07-31 2020-02-06 Colorado State University Research Foundation Compositions, methods and uses for modulating the tumor microenvironment to enhance antitumor immunity
CN111304324B (zh) * 2020-02-21 2021-05-14 温州医科大学 Alpl基因作为肺腺癌及其转移的诊治靶标的应用
BR112022022585A2 (pt) * 2020-05-08 2022-12-13 23 Ikigai Pte Ltd Métodos para a identificação de uma condição médica em um indivíduo humano
CN113069443A (zh) * 2021-04-12 2021-07-06 四川大学 奈必洛尔在制备预防和/或治疗口腔白斑及口腔鳞状细胞癌的药物中的用途
CN116859058A (zh) * 2023-07-17 2023-10-10 上海中医药大学 一种基于NDR1-Myc互作抗结直肠癌活性分子筛选方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4121547A1 (de) 1991-06-28 1993-01-14 Daimler Benz Ag Mehrschichtisolierfolie
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
US6004528A (en) 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
US6946475B1 (en) * 1999-04-07 2005-09-20 University Of Virginia Patent Foundation Anticancer calcium channel blockers
NZ521255A (en) 2000-03-06 2007-01-26 Univ Kentucky Res Found Methods to impair hematologic cancer progenitor cells and compounds related thereto
US6605589B1 (en) * 2000-03-31 2003-08-12 Parker Hughes Institute Cathepsin inhibitors in cancer treatment
AU2002250236A1 (en) 2001-03-02 2002-09-19 Medimmune, Inc. Cd2 antagonists for treatment of autoimmune or inflammatory disease
US6632832B1 (en) * 2002-09-10 2003-10-14 Dabur Research Foundation Anti-cancer activity of carvedilol and its isomers
AU2004229501B2 (en) 2003-04-11 2011-08-18 Medimmune, Llc Recombinant IL-9 antibodies and uses thereof
US9062056B2 (en) * 2008-09-09 2015-06-23 Boehringer Ingelheim International Gmbh Aza-benzimidazolone Chymase inhibitors
EP3118326B1 (en) * 2008-10-27 2020-04-29 Sapporo Medical University Molecular marker for cancer stem cell
WO2012030234A1 (en) * 2010-09-01 2012-03-08 Swee Thong Tan Methods and compositions for treating cancer
WO2013188715A2 (en) * 2012-06-13 2013-12-19 Herr John C Compositions and methods for treating cancer
WO2014205184A2 (en) * 2013-06-19 2014-12-24 University Of Miami Classification system, methods and kit for classifying. predicting and treating breast cancer

Also Published As

Publication number Publication date
EP3180000A1 (en) 2017-06-21
BR112017002724A2 (en) 2018-01-16
MX2017001954A (es) 2017-08-14
US10281472B2 (en) 2019-05-07
US20200041521A1 (en) 2020-02-06
CA2957930A1 (en) 2016-02-18
JP2017532368A (ja) 2017-11-02
EP3180000A4 (en) 2018-03-07
US20170234884A1 (en) 2017-08-17
WO2016024870A1 (en) 2016-02-18
CN106999471A (zh) 2017-08-01
KR20170040804A (ko) 2017-04-13
AU2015302419B2 (en) 2021-04-01
AU2015302419A1 (en) 2017-03-09
JP6899771B2 (ja) 2021-07-14
SG11201701035SA (en) 2017-03-30
SG10201901157QA (en) 2019-03-28

Similar Documents

Publication Publication Date Title
CL2017000373A1 (es) Diagnóstico de cáncer y terapia.
PH12019501959A1 (en) Therapeutic rna
JOP20200192A1 (ar) أجسام مضادة لـ tigit
ECSP17073743A (es) Moduladores de k-ras
PH12017500858A1 (en) Mocrocyclic peptides useful as immunomodulators
MY192927A (en) Fused bicyclic compounds for the treatment of disease
GEAP202114132A (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
NZ758528A (en) Bicyclic heterocycle compounds and their uses in therapy
UY34780A (es) Vectores virales para el tratamiento de distrofia retiniana
SG10201806849WA (en) Cyclopropylamines as lsd1 inhibitors
EA201400178A1 (ru) Лечение рака молочной железы
MX2016004570A (es) Uso de inhibidores del bromodominio de cbp/ep300 para la inmunoterapia del cáncer.
MX2017008456A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
UY34616A (es) Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
PH12016501769A1 (en) Treatment of intrahepatic cholestatic diseases
MY195000A (en) Method for the treatment of neurological disease
TW201613587A (en) Medical treatments based on anamorelin
TW201613949A (en) Targeting microRNAs for metabolic disorders
MY167383A (en) Disposable diaper
SG10201908881PA (en) Fused bicyclic compounds for the treatment of disease
MX2016002931A (es) Moduladores del receptor x hepatico (lxr).
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
AR120118A2 (es) Anticuerpos anti tigit
HK1239566A1 (en) Cancer diagnosis and therapy
EA201992022A1 (ru) Терапевтическая рнк